These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18813284)

  • 1. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia.
    Leaf DE; Goldfarb DS
    Kidney Int; 2009 Jan; 75(1):15-24. PubMed ID: 18813284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of anemia correction with health related quality of life in patients not on dialysis.
    Alexander M; Kewalramani R; Agodoa I; Globe D
    Curr Med Res Opin; 2007 Dec; 23(12):2997-3008. PubMed ID: 17958944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis.
    Collister D; Komenda P; Hiebert B; Gunasekara R; Xu Y; Eng F; Lerner B; Macdonald K; Rigatto C; Tangri N
    Ann Intern Med; 2016 Apr; 164(7):472-8. PubMed ID: 26881842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
    Wish JB; Coyne DW
    Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Anemia Treatment on Health-Related Quality of Life in Patients With Chronic Kidney Disease in the Contemporary Era.
    Finkelstein FO; Finkelstein SH
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):250-252. PubMed ID: 31477255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life and hemoglobin levels in chronic kidney disease patients.
    Finkelstein FO; Story K; Firanek C; Mendelssohn D; Barre P; Takano T; Soroka S; Mujais S
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):33-8. PubMed ID: 18987300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review.
    Gandra SR; Finkelstein FO; Bennett AV; Lewis EF; Brazg T; Martin ML
    Am J Kidney Dis; 2010 Mar; 55(3):519-34. PubMed ID: 20031287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.
    Kliger AS; Fishbane S; Finkelstein FO
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):354-7. PubMed ID: 22266571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
    Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
    Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
    Doss S; Schiller B
    Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
    Schmid H; Schiffl H; Lederer SR
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in patients on hemodialysis and peritoneal dialysis.
    Okpechi IG; Nthite T; Swanepoel CR
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):519-26. PubMed ID: 23640624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks.
    Locatelli F; Gascón P
    Oncologist; 2009; 14 Suppl 1():57-62. PubMed ID: 19762517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of renal anemia in progression of chronic kidney disease].
    Racki S; Maleta I
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():33-7. PubMed ID: 20235353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An expert opinion on the current treatment of anemia in patients with kidney disease.
    Locatelli F; Del Vecchio L
    Expert Opin Pharmacother; 2012 Mar; 13(4):495-503. PubMed ID: 22296648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life and anemia: the nephrology experience.
    Macdougall IC
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):39-42. PubMed ID: 9671329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Erythropoesis-stimulating agents: past, present and future].
    Kes P; Basić-Jukić N
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():3-6. PubMed ID: 20235351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.